EI
ALNY icon

EAM Investors’s Alnylam Pharmaceuticals ALNY Stock Holding History

EAM Investors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-21,933
Closed -$1.41M – 308
2013
Q4 		$1.41M Buy
21,933
+1,798
+9% +$107K 0.25% 170
2013
Q3 		$1.29M Sell
20,135
-44,031
-69% -$2.19M 0.26% 154
2013
Q2 		$1.99M Buy
+64,166
New +$1.71M 0.43% 59

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EAM Investors's ALNY Position: Q1 2014 in Review

EAM Investors sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2014, closing a stake of 21,933 shares — an estimated $1.41M sold.

EAM Investors first reported a position in ALNY in Q2 2013 and held it in 3 quarters. The position peaked at $1.99M in Q2 2013. 198 funds tracked by Wall St. Rank hold ALNY as of Q1 2014.

  • EAM Investors reported no remaining Alnylam Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • EAM Investors sold 21,933 Alnylam Pharmaceuticals shares in Q1 2014, an estimated $1.41M.
  • EAM Investors first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • EAM Investors's Alnylam Pharmaceuticals position peaked at $1.99M in Q2 2013.
  • 198 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2014.

Based on EAM Investors's 13F filing for Q1 2014, filed 15 May 2014.